← Guides

Thymosin Alpha-1 vs Beta-4: two different molecules

Thymosin alpha-1 and thymosin beta-4 are frequently confused for a trivial reason: they share the name 'thymosin', a historical label grouping peptides originally isolated from the thymus. But that shared surname hides two completely different molecules, with different structures, biological functions that do not overlap, and very separate regulatory status. Alpha-1 is a 28-amino-acid immunomodulatory peptide that, as thymalfasin (Zadaxin), has been registered as a prescription drug for decades in more than 30 countries; beta-4 is a 43-amino-acid actin-sequestering peptide studied for tissue repair, still experimental, and the parent of the shorter synthetic fragment TB-500. This guide clarifies how they differ, why they are not interchangeable, and how TB-500 fits into the beta-4 story. It is educational content: it includes no dosing and is not medical advice.

The 'thymosin' name misleads: they are different molecules

The starting point is to undo the confusion the name creates. 'Thymosin' does not name a specific molecule but a historical family of peptides isolated from the thymus while researchers were studying that organ's role in immunity. Under that umbrella sit molecules whose only kinship is the place where they were first described. Thymosin alpha-1 and thymosin beta-4 are the clearest example: they share the surname and almost nothing else. Alpha-1 is a 28-amino-acid chain derived from prothymosin alpha; beta-4 is a 43-amino-acid chain that plays a structural role in the cell, binding actin. Neither the sequence, nor the size, nor the biological function coincide. Treating them as variants of the same thing — which often happens in forums and catalogues — is a basic error: they are not the 'alpha version' and the 'beta version' of one peptide, but two separate chemical entities that old nomenclature left in the same drawer.

Alpha-1: immunomodulation with real clinical use outside the US

Thymosin alpha-1 is, above all, an immune-signaling molecule; it does not attack pathogens directly but recalibrates the immune system's response. In the literature it is described engaging Toll-like receptors (notably TLR2, TLR4 and TLR9) on dendritic cells, triggering cascades that shift cell maturation and cytokine output, help rebalance T-helper 1/T-helper 2 responses, and enhance the activity of cytotoxic T-cells and natural killer cells. What sets it apart from almost any other peptide in this ecosystem is its clinical track record: as thymalfasin, brand name Zadaxin, it has been registered for decades as a prescription drug for chronic hepatitis B and C and as an immune stimulant in China and more than 30 countries. Randomized trials and systematic reviews support that adjunct use, although effect sizes are often modest and study quality variable. The important nuance is geographic: despite repeated attempts, it never obtained FDA approval in the United States and is not authorized by the EMA in the EU, so its status depends critically on the country.

Beta-4: experimental tissue repair, and where TB-500 comes from

Thymosin beta-4 belongs to a different world: cellular architecture and tissue repair. Its main function in the cell is to sequester G-actin, the monomeric actin whose assembly governs the cytoskeleton and cell motility; from there it acts as a pleiotropic 'moonlighting' peptide that, in preclinical models, is linked to endothelial-cell migration, angiogenesis, anti-inflammatory signaling and cardiac and neural repair. This is where the relationship with TB-500 needs to be made clear, as it is the most common source of confusion. TB-500 is not a commercial synonym for beta-4: it is a shorter synthetic fragment, built around the molecule's active region, that is frequently marketed as if equivalent to the full 43-amino-acid peptide. It is not. The human evidence that exists corresponds to pharmaceutical formulations of full-length beta-4 — the RGN-259 (ophthalmic), RGN-352 (injectable) and RGN-137 (dermal) programs — all halted at early phases and none with marketing approval. Gray-market material labeled 'TB-500' is therefore a different fragment without that backing, not the studied molecule.

Two regulatory statuses that should not be mixed

The practical consequence of their being different molecules is that their legal and quality status differs too, and it is best not to carry conclusions from one to the other. Alpha-1 leads a double life: it is a registered prescription drug (thymalfasin/Zadaxin) in dozens of countries and, at the same time, in jurisdictions where it is not registered it circulates as 'research-use-only' (RUO) material. Beta-4, by contrast, has not reached any full approval in any market: it is experimental, and outside the proprietary trials it is RUO in virtually every jurisdiction. There is also a relevant difference in sport: beta-4 and its TB-500 fragment are prohibited at all times by the World Anti-Doping Agency as actin-binding/growth-factor peptides, whereas alpha-1 is not listed as a specific prohibited substance. In both cases, when the material comes from the gray market, the dominant risk is the usual one: unguaranteed identity, purity and labeling. With beta-4 a specific problem is added — that the product is actually the TB-500 fragment rather than the full sequence — so the minimum verification is a third-party Certificate of Analysis (identity, purity by HPLC, quantification and mass spectrometry) confirming which molecule is really in the vial.

Frequently asked questions

Are thymosin alpha-1 and beta-4 the same substance in two versions?

No. They share the name 'thymosin' for a historical reason — both were isolated from the thymus — but they are different molecules: alpha-1 has 28 amino acids and an immunomodulatory function, and beta-4 has 43 amino acids and binds actin for cell-structure and tissue-repair roles. They are not the 'alpha version' and 'beta version' of one peptide. This answer is educational, not medical advice.

How is TB-500 related to these two?

TB-500 is derived from thymosin beta-4, not from alpha-1. It is a shorter synthetic fragment, built around beta-4's active region, that is often sold as if equivalent to the full 43-amino-acid peptide; in reality it is a different molecule and does not carry the same evidence. Alpha-1 has no relationship to TB-500.

Is either of them approved for human use?

It depends on which one and where. Alpha-1 (thymalfasin/Zadaxin) is registered as a prescription drug for hepatitis B/C and immune indications in China and more than 30 countries, but it is not FDA-approved in the US or EMA-authorized in the EU. Beta-4 is experimental: it has only reached early-phase trials and no formulation holds full approval. Outside those registered uses, both circulate as 'research-use-only' (RUO) material. Status must always be checked locally. Educational information.

✓ Last reviewed · 2026-07-24